141345-08-6

Basic information

• Product Name: 4-CYCLOHEXYL-BUTYNE
• Synonyms: BUT-3-YNYL-CYCLOHEXANE;4-CYCLOHEXYL-BUTYNE;2-(4-methoxyphenyl)-8-(trifluoromethyl)cinchoninic acid;2-(4-methoxyphenyl)-8-(trifluoromethyl)quinoline-4-carboxylic acid;Cyclohexane, 3-butyn-1-yl-
• CAS NO: 141345-08-6
• Molecular Formula: C₁₀H₁₆
• Molecular Weight: 136.23
• Mol File: 141345-08-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 181°Cat760mmHg
• Flash Point: 52.5°C
• Appearance: /
• Density: 0.847g/cm³
• Vapor Pressure: 1.18mmHg at 25°C
• Refractive Index: 1.46
• CAS DataBase Reference: 4-CYCLOHEXYL-BUTYNE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYCLOHEXYL-BUTYNE(141345-08-6)
• EPA Substance Registry System: 4-CYCLOHEXYL-BUTYNE(141345-08-6)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-51/53
• Safety Statements: 61
• Hazardous Substances Data: 141345-08-6(Hazardous Substances Data)

Usage

General Description

4-CYCLOHEXYL-BUTYNE, also known as 4-cyclohexyl-1-butyne, is an organic compound with the chemical formula C10H16. It is a colorless liquid with a molecular weight of 136.23 g/mol. This chemical is primarily used as a synthetic intermediate in the production of other organic compounds and can also be used in various industrial applications. It is important to handle 4-CYCLOHEXYL-BUTYNE with caution as it is flammable and may cause irritation to the skin and eyes upon contact. 4-CYCLOHEXYL-BUTYNE should be stored and handled in a well-ventilated area and personal protective equipment should be worn when working with it.

InChI:InChI=1/C10H16/c1-2-3-7-10-8-5-4-6-9-10/h1,10H,3-9H2

Upstream product

• 1647-26-3 1-bromo-2-cyclohexylethane 
• 1216963-74-4 lithium acetylide-ethylenediamine complex 
• 4202-14-6 dimethyl (2-oxopropyl)phosphonate 
• 4361-28-8 3-cyclohexylpropanal 
• 4442-79-9 cyclohexylethan-1-ol 
• 952688-12-9 C₁₀H₁₆Br₂ 
• 1124-63-6 3-cyclohexylpropan-1-ol 

Downstream Products

• 141345-14-4 2-(4-cyclohexyl-1-butyn-1-yl)adenosine 
• 451501-41-0 (4E,6E)-9-cyclohexylnona-4,6-dienal 
• 1678-93-9 butylcyclohexane 
• 104-51-8 1-butylbenzene 
• 141345-29-1 9-(2,3,5-tri-O-acetyl-1-β-D-ribofuranosyl)-6-chloro-2-(4-cyclohexyl-1-butyn-1-yl)purine 

Relevant articles and documents

Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents

The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, the invention relates to compounds, compositions thereof, and methods for selectively enhancing fungal sensitivity to antifungal compounds. The compositions of the invention are comprised of a combination of a histone deacetylase inhibitor, or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt, agricultural formulation, prodrug or complex thereof, and an antifungal agent, the histone deacetylase inhibitor being a compound of Formula (I):

Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: Adenosine A2 receptor agonists with potent antihypertensive effects

Adenosine receptor-binding profiles in rat brain tissues and antihypertensive effects in spontaneously hypertensive rats (SHR) of a series of 2-(cycloalkylalkynyl)adenosine (2-CAAs) and their congeners are described. The structure-activity relationship of this series of compounds is discussed, focusing on the length of the alkynyl side chain and bulkiness of the terminal cycloalkyl substituents in terms of binding activity and cardiovascular effects. All the 2-CAAs had a preferential affinity for A2 receptors. Of these derivatives, 2-(3-cyclopentyl-1-propyn-1-yl)adenosine (10b) exhibited the most selective affinity for A2 receptors (K(i) ratio: A1/A2 = 70) on the basis of receptor binding. In the C-2 binding region of adenosine, compounds often have potent and/or selective A2 activity from introduction of an acetylenic group at the C-2 position followed by one methylene residue further followed by a hydrophobic substituent such as a cycloalkyl ring at the terminal position of the alkynyl side chain. Intravenous injection of 10b up to 100 μg/kg had a potent hypotensive effect without a marked decrease in heart rate in anesthetized SHR. Compounds 10j-s, with a hydroxyl group in the C-3 position of the alkynyl side chain, had a potent affinity for both A1 and A2 receptors, but they were not highly selective for A2 receptors. These compounds caused a marked bradycardia upon intravenous administration in anesthetized SHR. Oral administration of 10b (0.1-1 mg/kg) had a potent and long-lasting antihypertensive effect in conscious SHR.